FY2020 EPS Estimates for Theravance Biopharma Inc (TBPH) Cut by Analyst
Theravance Biopharma Inc (NASDAQ:TBPH) – Research analysts at Piper Jaffray Companies cut their FY2020 EPS estimates for Theravance Biopharma in a note issued to investors on Sunday, November 11th. Piper Jaffray Companies analyst T. Van. Buren now forecasts that the biopharmaceutical company will post earnings per share of ($3.05) for the year, down from their previous forecast of ($3.00). Piper Jaffray Companies currently has a “Buy” rating on the stock.
Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings data on Tuesday, November 6th. The biopharmaceutical company reported ($1.10) EPS for the quarter, topping the consensus estimate of ($1.18) by $0.08. The firm had revenue of $12.84 million during the quarter, compared to analyst estimates of $10.55 million. Theravance Biopharma had a negative return on equity of 505.90% and a negative net margin of 513.41%.
NASDAQ:TBPH opened at $25.48 on Wednesday. The company has a quick ratio of 3.08, a current ratio of 3.26 and a debt-to-equity ratio of 6.52. The firm has a market capitalization of $1.42 billion, a PE ratio of -4.68 and a beta of 2.09. Theravance Biopharma has a one year low of $21.27 and a one year high of $35.48.
In other news, EVP Bradford J. Shafer sold 7,119 shares of the company’s stock in a transaction on Monday, August 27th. The stock was sold at an average price of $27.71, for a total value of $197,267.49. Following the completion of the sale, the executive vice president now directly owns 84,000 shares in the company, valued at approximately $2,327,640. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Philip D. Worboys sold 6,393 shares of the company’s stock in a transaction on Wednesday, September 12th. The stock was sold at an average price of $28.50, for a total value of $182,200.50. Following the completion of the sale, the senior vice president now owns 166,753 shares of the company’s stock, valued at $4,752,460.50. The disclosure for this sale can be found here. Corporate insiders own 6.90% of the company’s stock.
Hedge funds have recently modified their holdings of the business. UBS Group AG increased its stake in Theravance Biopharma by 88.4% in the 1st quarter. UBS Group AG now owns 4,511 shares of the biopharmaceutical company’s stock worth $109,000 after buying an additional 2,117 shares in the last quarter. United Services Automobile Association purchased a new stake in Theravance Biopharma in the 3rd quarter worth $210,000. Xact Kapitalforvaltning AB purchased a new stake in Theravance Biopharma in the 1st quarter worth $202,000. Man Group plc purchased a new stake in Theravance Biopharma in the 3rd quarter worth $292,000. Finally, Royal Bank of Canada increased its stake in Theravance Biopharma by 22.3% in the 1st quarter. Royal Bank of Canada now owns 16,664 shares of the biopharmaceutical company’s stock worth $404,000 after buying an additional 3,042 shares in the last quarter. Institutional investors and hedge funds own 84.72% of the company’s stock.
Theravance Biopharma Company Profile
Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria.
Featured Article: How to Invest in Growth Stocks
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.